Nuvectis Pharma, Inc. (NVCT) · Nov 4, 2026 · Earnings
Miss — GAAP EPS $(1.02) vs approximately $(0.22) consensus; $20.0M license payment included
Nuvectis’ third-quarter earnings missed consensus because of upfront license costs, while $140.7 million in cash funds its next clinical and FDA milestones.
Nuvectis is transitioning from a small early-stage oncology company into a late-stage clinical platform built around newly licensed assets NXP100 and NXP200, backed by a July financing that was already known before this report. The filing mainly confirms that transition is funded, while adding clinical updates and near-term regulatory milestones.
The headline earnings result is a clear miss, but the comparison is distorted by deal accounting. GAAP loss per share was $1.02 versus a published consensus loss of roughly $0.22, making this a formal earnings miss. The company says the quarter included a $20.0 million upfront payment for the NXP100/NXP200 license and $1.8 million in NXP900 milestones, so the reported loss does not represent the underlying quarterly development burn alone.
| Figure | Q3 2026 | Q3 2025 | Consensus |
|---|---|---|---|
| Diluted EPS (Statement of Operations) | $(1.02) | $(0.44) | $(0.22) |
| Net loss (Statement of Operations) | $(30.1M) | $(7.5M) | |
| R&D expense (Statement of Operations) | $27.4M | $5.8M | |
| Cash and equivalents (Balance Sheet) | $140.7M |
The balance sheet is the more important business update. Cash rose to $140.7 million after the follow-on offering and ATM activity, giving Nuvectis substantially more capacity to execute its expanded pipeline rather than immediately return to the capital markets. The company says that cash is expected to fund operations into the second half of 2029.
The clinical story advances, but this is still a milestone setup rather than a proof point. NXP100 has China approval in one PNH population, while the U.S. path remains dependent on ongoing FDA discussions; NXP200's reported Phase 1b activity is encouraging but comes from a small 27-patient dataset. The filing points to an FDA update and U.S. IND submissions by year-end, which are the next events capable of converting the newly funded platform into concrete regulatory progress. 〔0〕 〔1〕
Bottom line: This is a formal earnings miss, but mostly because Nuvectis paid for the pipeline it is now funded to develop. The business story is modestly better on liquidity and execution, though the key U.S. regulatory steps remain ahead rather than delivered.
FDA update and U.S. IND submissions expected by year-end
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!